Optimizing CLL Patient Outcomes in Practice: Interprofessional Strategies for the Oncology Care Team

• Examine relevant prognostic factors in chronic lymphocytic leukemia (CLL) and assess the importance of molecular testing to guide clinical decision making and treatment selection.
• Appraise the latest trial data and practice guidelines for the use of novel, targeted agents in CLL and analyze strategies to optimize therapy selection based on clinical factors and patient preferences.
• Explore key clinical pearls and differentiating factors between novel, targeted therapies in CLL, and discuss practical solutions and innovations to mitigate factors that may complicate the use of the most clinically appropriate therapy.
• Appraise multidisciplinary strategies to optimize testing, treatment selection, management, and continuum of care for CLL patients and strategies to increase collaboration with the team including specialists (e.g., cardiology) and oncology clinicians of various practice settings.

Supported through an independent educational grant from AstraZeneca.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners/Faculty

Sandra E. Kurtin, PhD, ANP-C, AOCN–has disclosed that she is an advisor or consultant to Abbvie, Amgen, AstraZeneca, BMS, GSK, and lncyte.

Lauren Willis, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.

Jennifer A. Woyach, MD–has disclosed that she is a consultant for Abbvie, AstraZeneca, Beigene, Genetech, Janssen, Loxo, Pharmacyclics, and Newave. She receives grant/research support from Janssen, Karyopharm, Morphosys, Pharmacyclics, and Schrodinger.

Peer Review

Katherine Lee, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:

Susan Gitzinger, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity